公开(公告)号：AU637791B2

公开(公告)日：1993-06-10

申请号：AU5278090

申请日：1990-03-01

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： JOSEPH F. SAMBROOK ,  EDWIN L. MADISON ,  ELIZABETH J. GOLDSMITH ,  MARYJANE H. GETHING ,  ROBERT D. GERARD

IPC: A61K38/46 ,  A61K31/00 ,  A61K38/00 ,  A61P7/00 ,  A61P7/02 ,  A61P9/10 ,  C07H21/04 ,  C07K14/005 ,  C07K14/195 ,  C07K14/47 ,  C07K14/81 ,  C12N9/04 ,  C12N9/50 ,  C12N9/64 ,  C12N9/72 ,  C12N9/76 ,  C12N9/99 ,  C12N15/09 ,  C12N15/10 ,  C12N15/57 ,  C12N15/58 ,  C12N15/71 ,  C12N15/85 ,  C12R1/91

Abstract: The present invention relates to serine protease mutants of the chymotrypsin superfamily, particularly t-PA mutants that are resistant to inhibition by their cognate inhibitors, such as PAI-1 in the case of t-PA, and genes that encode the same. The invention also relates to serine protease inhibitor mutants, particularly PAI-1 mutants that inhibit the serine protease mutants of the present invention, particularly t-PA mutants, and genes that encode the same. The serine protease mutants and serine protease inhibitor mutants are useful as, e.g., pharmacological agents.